Bruce Connop, Ph.D., Vice President, Toxicology, Strategy, & Development, Pharmaceuticals & Healthcare
- Seasoned drug development executive with over 25 yrs of Biotech and Pharmaceutical experience
- Proven record of success at various stages of drug development through to BLA/NDA approval
- Subject Matter Lead for non-clinical development and clinical pharmacology programs to support clinical advancement through to commercialization
- Extensive experience with large Pharma partnerships for over 10 years (Lilly and Pfizer; Subject Matter Lead). Development of Ngenla™ (long-acting human growth hormone) with Pfizer
- Proficient in translating scientific results into commercial value resulting in high levels of responsibility. Exceptional organizational and communication skills
- Advance objectives through effective management of internal teams as well as contract research organizations and external collaborations
- Leader with scientific expertise in many areas of drug development; analytical methods, formulation development, DMPK, regulatory toxicology, clinical immunogenicity and bioanalytics/pharmacokinetics
- Member of Senior Joint Development Committees with Pharma collaborators (Lilly, Novo Nordisk, Pfizer, etc.) as well as Subject Matter Lead for Manufacturing (early phase), Non-clinical Development and Clinical Pharmacology through to BLA/NDA
